Jiezlab Showcases "Dual-Track" Diagnostic Innovation at CACLP 2026, Garnering Global Industry Traction


Release time:

2026-03-27

Jiezlab Showcases "Dual-Track" Diagnostic Innovation at CACLP 2026, Garnering Global Industry Traction

Xiamen, China — The 23rd China International Exhibition of Clinical Laboratory Medicine and Transfusion Medicine (CACLP 2026) officially commenced at the Xiamen International Expo Center. As a premier global platform for In-Vitro Diagnostics (IVD), the event highlights cutting-edge laboratory technology. 

 

Yantai Jiezi Biotechnology Co., Ltd. (Jiezlab Diagnostics) took center stage by debuting its comprehensive portfolio of leading solutions backed by robust research and development, along with proven reliability in the field.

Precision in Human Diagnostics

 

Jiezlab’s exhibit centered around its two key technological pillars: Microfluidic Dry Chemistry Analyzer and Microfluidic Immunofluorescence Analyzer. Designed for high-efficiency clinical workflows, these systems combine a solid technical foundation with streamlined operation. The lineup attracted significant interest from industry experts and international delegations, fostering high-level discussions on-site and underscoring Jiezlab’s expanding presence in the clinical testing market.

 

Strategic Expansion into Veterinary Care

 

In addition to human diagnostics, Jiezlab showcased its specialized veterinary dry chemistry and immunofluorescence solutions. Specifically tailored for routine animal healthcare, offering rapid and reliable diagnostics with a user-friendly interface. The veterinary testing line received particularly positive feedback for its practical design and high clinical utility.

 

Commitment to Global Innovation

 

Jiezlab’s presence at CACLP 2026 reinforces its commitment to delivering high-quality diagnostics. By maintaining a "dual-track" focus on both human and animal diagnostics, the company continues to lead innovation and strengthen its engagement with the global diagnostic community.